Cited by 1,683Angiogenesis and VEGF in CancerCancer Cells and MetastasisMathematical Biology Tumor Growth

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

Boehm, Thomas, Folkman, Judah, Browder, Timothy, O'Reilly, Michael S.·1997·Nature

Open this paper in CoChat — free account

Abstract

Acquired drug resistance is a major problem in the treatment of cancer. Of the more than 500,000 annual deaths from cancer in the United States, many follow the development of resistance to chemotherapy. The emergence of resistance depends in part on the genetic instability, heterogeneity and high mutational rate of tumour cells. In contrast, endothelial cells are genetically stable, homogeneous and have a low mutational rate. Therefore, antiangiogenic therapy directed against a tumour's endothelial cells should, in principle, induce little or no drug resistance. Endostatin, a potent angiogenesis inhibitor, was administered to mice bearing Lewis lung carcinoma, T241 fibrosarcoma or B16F10 melanoma. Treatment was stopped when tumours had regressed. Tumours were then allowed to re-grow and endostatin therapy was resumed. After 6, 4 or 2 treatment cycles, respectively, no tumours recurred after discontinuation of therapy. These experiments show that drug resistance does not develop in three tumour types treated with a potent angiogenesis inhibitor. An unexpected finding is that repeated cycles of antiangiogenic therapy are followed by prolonged tumour dormancy without further therapy.

Integrity signals

Registry

Crossref · 10.1038/37126

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509
Self-citation
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Self-citation
Thomas, Springfield, Illinois
MAGOUN, H. N. (1965) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196504000-00011 · Cited by 2,932
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,251
Self-citation
Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,891
Self-citation
Angiostatin induces and sustains dormancy of human primary tumors in mice
O’Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,170
Self-citation
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 443
Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas.
Singh, R. K., Gutman, M., BUCANA, C. D., Sanchez, R. R., Llansa, N., & Fidler, I. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4562 · Cited by 437
Tumor angiogenesis and tissue factor
Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0296-167 · Cited by 290
Self-citation
Current results of the screening program at the division of cancer treatment, national cancer institute
GOLDIN, A. S., Venditti, J. M., Macdonald, J. S., Muggia, F. M., Henney, J. E., & DeVita, V. T. (1981) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(81)90027-x · Cited by 209

Flagged first, then by citations

Show all 12 references

Research works printed but not linked: 3

Li, P. L., Schneider, J. A. & Kantor, A. F. in Cancer Medicine 3rd edn Vol. 1(eds Holland, J. F. et al.) 322–339 (Lea & Febiger, Philadelphia, (1993)).
Morrow, C. S. & Cowan, K. H. in Cancer Medicine 3rd edn. Vol. 1(eds Holland, J. F. et al.) 618–630 (Lea & Febiger, Philadelphia, (1993)).
Brem, H., Goto, F., Budson, A., Saunders, L. & Folkman, J. Minimal drug resistance after prolonged anti-angiogenic therapy with AGM-1470. Surg. Forum XLV, 674–677 (1994).

Sorted by citations

Role of angiogenesis in tumor growth and metastasis
Folkman, J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70065-1 · Cited by 2,904
Self-citation
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,299
Self-citation
Adipose tissue remodeling and obesity
Sun, K., Kusminski, C. M., & Scherer, P. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45887 · Cited by 1,941
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Self-citation
Clinical translation of angiogenesis inhibitors
Kerbel, R. S., & Folkman, J. (2002) · Nature reviews. Cancer · doi:10.1038/nrc905 · Cited by 1,538
Self-citation
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,499
Angiogenesis in cancer
Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.213 · Cited by 1,509
The sweet and sour of cancer: glycans as novel therapeutic targets
Fuster, M. M., & Esko, J. D. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1649 · Cited by 1,389
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z., Chen, H., Zheng, L., Sun, L., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,486
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,234
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1821 · Cited by 1,239
Angiogenesis
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Self-citation
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
Klement, G. L., Baruchel, S., Rak, J. W., Man, S., Clark, K., Hicklin, D. J., Böhlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,166
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
Ravi, R. K., Mookerjee, B., Bhujwalla, Z. M., Sutter, T. R., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · PubMed Central · Cited by 1,099
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,074
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
Jiménez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., & Bouck, N. (2000) · Nature Medicine · doi:10.1038/71517 · Cited by 1,014
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Self-citation
Tumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 985
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts
Lyden, D. C., Young, A. Z., Zagzag, D., Yan, W. X., Gerald, W. L., O'Reilly, R., Bader, B., Hynes, R. O., Zhuang, Y., Manova, K., et al. (1999) · Nature · doi:10.1038/44334 · Cited by 912
Contagious Speculation and a Cure for Cancer: A Nonevent that Made Stock Prices Soar
Huberman, G., & Regev, T. (2001) · The Journal of Finance · doi:10.1111/0022-1082.00330 · Cited by 887
Adipose tissue mass can be regulated through the vasculature
Rupnick, M. A., Panigrahy, D., Zhang, C.-Y., Dallabrida, S. M., Lowell, B. B., Langer, R., & Folkman, M. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162349799 · Cited by 845
Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation
Griffioen, A. W., & Molema, G. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01448-0 · Cited by 843
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R. S., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 860
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
Hlatky, L. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.12.883 · Cited by 786
Angiogenesis: regulators and clinical applications
Liekens, S., De Clercq, E., & Neyts, J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00529-3 · Cited by 748
Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 746
Matrix metalloproteinase degradation of extracellular matrix: biological consequences
Shapiro, S. D. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80035-5 · Cited by 714
Angiogenesis Inhibitors Endostatin or TNP-470 Reduce Intimal Neovascularization and Plaque Growth in Apolipoprotein E–Deficient Mice
Moulton, K. S., Heller, E., Konerding, M. A., Flynn, E., Palinski, W., & Folkman, J. (1999) · Circulation · doi:10.1161/01.cir.99.13.1726 · Cited by 688
Self-citation
Vasculogenic Mimicry and Tumor Angiogenesis
Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 682
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 674
Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action
Folkman, J. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.015 · Cited by 675
Self-citation
Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy.
Hahnfeldt, P., Panigrahy, D., Folkman, J., & Hlatky, L. (1999) · PubMed · Cited by 654
Self-citation
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 657
NOTCH Pathway Blockade Depletes CD133-Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts
Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., Koh, C. M., Zhang, J., Li, Y., Maciaczyk, J., et al. (2009) · Stem Cells · doi:10.1002/stem.254 · Cited by 673
The CCN Family of Angiogenic Regulators: The Integrin Connection
Lau, L. F., & Lam, S. C.-T. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4456 · Cited by 645
Targeting tumor‐associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
Tyrosine kinase – Role and significance in Cancer
Paul, M. K., & Mukhopadhyay, A. K. (2004) · International Journal of Medical Sciences · doi:10.7150/ijms.1.101 · Cited by 627
The molecular biology of cancer
Bertram, J. S. (2000) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(00)00007-8 · Cited by 610
Endostatin Induces Endothelial Cell Apoptosis
Dhanabal, M., Ramchandran, R., Waterman, M. J. F., Lu, H. A. J., Knebelmann, B., Segal, M. S., & Sukhatme, V. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11721 · Cited by 582
Acoustic droplet vaporization for therapeutic and diagnostic applications
Kripfgans, O. D., Fowlkes, J. B., Miller, D. L., Eldevik, O. P., & Carson, P. L. (2000) · Ultrasound in Medicine & Biology · doi:10.1016/s0301-5629(00)00262-3 · Cited by 567
Endogenous Inhibitors of Angiogenesis
Nyberg, P., Xie, L., & Kalluri, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2427 · Cited by 557
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
Lever, A. F., Hole, D. J., Gillis, C. R., McCallum, I. R., McInnes, G. T., MacKinnon, P. L., Meredith, P., Murray, L. S., Reid, J. L., & Robertson, J. W. K. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03228-0 · Cited by 542
Basement membrane proteoglycans: from cellar to ceiling
Iozzo, R. V. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1702 · Cited by 521
Landscaping the Cancer Terrain
Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.280.5366.1036 · Cited by 519
Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1
Arnold, R. S., Shi, J., Murad, E., Whalen, A. M., Sun, C. Q., Polavarapu, R., Parthasarathy, S., Petros, J. A., & Lambeth, J. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101505898 · Cited by 486
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Chang, S. S., O’Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (1999) · PubMed · Cited by 465
Cancer as a robust system: implications for anticancer therapy
Kitano, H. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1300 · Cited by 456
Interaction of endostatin with integrins implicated in angiogenesis
Rehn, M., Veikkola, T., Kukk, E., Nakamura, H., Ilmonen, M., Lombardo, C. R., Pihlajaniemi, T. A., Alitalo, K. K., & Vuori, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1024 · Cited by 455
Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism
Lee, A. Y. Y., Rickles, F. R., Julian, J. A., Gent, M., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M. H., & Levine, M. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.133 · Cited by 452
Role of Integrins in Cancer: Survey of Expression Patterns
Mizejewski, G. J. (1999) · Proceedings of The Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.1999.d01-122.x · Cited by 449
Endostatin inhibits VEGF‐induced endothelial cell migration and tumor growth independently of zinc binding
Yamaguchi, N., Anand‐Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., Que, I., Lowik, C., Timpl, R., & Olsen, B. R. (1999) · The EMBO Journal · doi:10.1093/emboj/18.16.4414 · Cited by 440
Vascular Growth Factors and Lymphangiogenesis
Jussila, L., & Alitalo, K. K. (2002) · Physiological Reviews · doi:10.1152/physrev.00005.2002 · Cited by 448
Vasculogenesis and Angiogenesis
Patan, S. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_1 · Cited by 447
Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1
Kim, Y. M., Hwang, S., Kim, Y.-M., Pyun, B., Kim, T., Lee, S., Gho, Y. S., & Kwon, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202771200 · Cited by 429
Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin
O’Reilly, M. S., Pirie-Shepherd, S. R., Lane, W. S., & Folkman, J. (1999) · Science · doi:10.1126/science.285.5435.1926 · Cited by 429
Self-citation
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 428
Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor
Pettersson, A. F., Nagy, J. A., Brown, L. F., Sundberg, C., Morgan, E. S., Jungles, S., Carter, R., Krieger, J. E., Manseau, E. J., Harvey, V. S., et al. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780013 · Cited by 412
Cell surface tumor endothelial markers are conserved in mice and humans.
Carson-Walter, E. B., Watkins, D. N., Nanda, A., Vogelstein, B., Kinzler, K. W., & Croix, B. S. (2001) · PubMed · Cited by 410
3D tumour models: novel in vitro approaches to cancer studies
Nyga, A., Cheema, U., & Loizidou, M. (2011) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-011-0132-4 · Cited by 414
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205108 · Cited by 400
Angiogenesis Ischemic and Neoplastic Disorders
Semenza, G. L. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152418 · Cited by 386
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080161 · Cited by 392
Vasculogenesis and Angiogenesis as Mechanisms of Vascular Network Formation, Growth and Remodeling
Patan, S. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006493130855 · Cited by 397
The onset and extent of genomic instability in sporadic colorectal tumor progression
Stoler, D. L., Chen, N., Basik, M., Kahlenberg, M. S., Rodrı́guez-Bigas, M. A., Petrelli, N. J., & Anderson, G. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15121 · Cited by 380
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 376
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.
Gutheil, J. C., Campbell, T. N., Pierce, P. R., Watkins, J. D., Huse, W. D., Bodkin, D., & Cheresh, D. A. (2000) · PubMed · Cited by 369
A cancer therapy resistant to resistance
Kerbel, R. S. (1997) · Nature · doi:10.1038/36978 · Cited by 368
Liposomal paclitaxel formulations
Koudelka, Š., & Tuřánek, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.006 · Cited by 366
Key factors in the acquisition of contrast kinetic data for oncology
Evelhoch, J. L. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3 · Cited by 366
Continuous release of endostatin from microencapsulated engineered cells for tumor therapy
Joki, T., Machluf, M., Atala, A., Zhu, J., Seyfried, N. T., Dunn, I. F., Abe, T., Carroll, R. S., & Black, P. M. (2001) · Nature Biotechnology · doi:10.1038/83481 · Cited by 364
Mathematical modeling of tumor-induced angiogenesis
Mantzaris, N. V., Webb, S., & Othmer, H. G. (2004) · Journal of Mathematical Biology · doi:10.1007/s00285-003-0262-2 · Cited by 370
Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data
Margolin, K. A., Gordon, M. S., Holmgren, E. B., Gaudreault, J., Novotny, W. F., Fyfe, G., Adelman, D. C., Stalter, S., & Breed, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.851 · Cited by 360
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
Xie, C., Wan, X., Quan, H., Zheng, M., Li, F., Li, Y., & Lou, L. (2018) · Cancer Science · doi:10.1111/cas.13536 · Cited by 352
Angiogenesis of Breast Cancer
Schneider, B. P., & Miller, K. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.017 · Cited by 348
Syndecans in inflammation
Götte, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0739rev · Cited by 358
Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials.
Liu, J., Wang, Y., Akamatsu, Y., Lee, C. C., Stetler, R. A., Lawton, M. T., & Yang, G.-Y. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.11.004 · Cited by 335
Protein N-terminal methionine excision
Giglione, C., Boularot, A., & Meinnel, T. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-3466-8 · Cited by 335
The biology of the combretastatins as tumour vascular targeting agents
Tozer, G. M., Kanthou, C., Parkins, C. S., & Hill, S. A. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00211.x · Cited by 331
Initial Stages of Tumor Cell-Induced Angiogenesis: Evaluation Via Skin Window Chambers in Rodent Models
Li, C., Shan, S., Huang, Q., Braun, R. D., Lanzen, J. L., Hu, K., Lin, P. C., & Dewhirst, M. W. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.2.143 · Cited by 331
Structure, function and tissue forms of the C‐terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin
Sasaki, T., Fukai, N., Mann, K., Göhring, W., Olsen, B. R., & Timpl, R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.15.4249 · Cited by 330
Tumor Invasion: Role of Growth Factor-Induced Cell Motility
Wells, A. H. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)61023-4 · Cited by 329
Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved
Kerbel, R. S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.213 · Cited by 324
‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents
Tosetti, F., Ferrari, N., Flora, S. D., & Albini, A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0300rev · Cited by 325
Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase.
Kim, Y. M., Jang, J.-W., Lee, O., Yeon, J.-H., Choi, E.-Y., Kim, K., Lee, S., & Kwon, Y. (2000) · PubMed · Cited by 315
Therapeutic cancer targeting peptides
Aina, O. H., Sroka, T. C., Chen, M., & Lam, K. S. (2002) · Biopolymers · doi:10.1002/bip.10257 · Cited by 313
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Resveratrol Isolated from Polygonum cuspidatum Root Prevents Tumor Growth and Metastasis to Lung and Tumor-Induced Neovascularization in Lewis Lung Carcinoma-Bearing Mice
Kimura, Y., & Okuda, H. (2001) · Journal of Nutrition · doi:10.1093/jn/131.6.1844 · Cited by 311
Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth
Pike, S. E., Yao, L., Jones, K. D., Cherney, B., Appella, E., Sakaguchi, K., Nakhasi, H. L., Teruya‐Feldstein, J., Wirth, P. J., Gupta, G., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2349 · Cited by 310
Inhibition of Human Lung Cancer Cell Growth by the Peroxisome Proliferator-Activated Receptor-γ Agonists through Induction of Apoptosis
Tsubouchi, Y., Sano, H., Kawahito, Y., Mukai, S., Yamada, R., Kohno, M., Inoue, K., Hla, T., & Kondo, M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2436 · Cited by 312
Still More Complexity in Mammalian Basement Membranes
Erickson, A., & Couchman, J. (2000) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540004801001 · Cited by 303
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino, F., Brignole, C., Marimpietri, D., Cilli, M., Gambini, C., Ribatti, D., Longhi, R., Allen, T. M., Corti, A., & Ponzoni, M. (2003) · PubMed · Cited by 296
Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
Blezinger, P., Wang, J., Gondo, M., Quezada, A., Mehrens, D., French, M., Singhal, A. K., Sullivan, S. M., Rolland, A. P., Ralston, R., et al. (1999) · Nature Biotechnology · doi:10.1038/7895 · Cited by 296
Mechanism and its regulation of tumor-induced angiogenesis
Gupta, M. K. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i6.1144 · Cited by 295
Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis
Tournaire, R., Demangel, C., Malavaud, B. A., Vassy, R., Rouyre, S., Kraemer, M., Plouët, J., Derbin, C., Perret, G. Y., & Mazié, J. C. (2000) · The EMBO Journal · doi:10.1093/emboj/19.7.1525 · Cited by 295
Conditional mouse models of sporadic cancer
Jonkers, J., & Berns, A. J. M. (2002) · Nature reviews. Cancer · doi:10.1038/nrc777 · Cited by 299
Antiangiogenic Activity of Restin, NC10 Domain of Human Collagen XV: Comparison to Endostatin
Ramchandran, R., Dhanabal, M., Volk, R., Waterman, M. J. F., Segal, M. S., Lu, H. A. J., Knebelmann, B., & Sukhatme, V. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0248 · Cited by 290

Authors: Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S.
Affiliations: Harvard University (US)
Dana-Farber/Harvard Cancer Center (US)
Corresponding author: Boehm, Thomas
ORCID: Boehm, Thomas
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1997-11
Volume: 390
Issue: 6658
Pages: 404-407
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/37126
OpenAlex: W1579297325
Cited by: 1,683
References: 12
Citations by year: 2026: 1 · 2025: 4 · 2024: 11 · 2023: 19 · 2022: 9 · 2021: 19 · 2020: 16 · 2019: 18 · 2018: 15 · 2017: 24 · 2016: 35 · 2015: 25 · 2014: 30 · 2013: 48 · 2012: 47
FWCI: 40.79
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords: anti-angiogenic therapy, acquired drug resistance, endostatin, angiogenesis inhibitors, tumor dormancy, Lewis lung carcinoma, B16F10 melanoma, tumor recurrence, endothelial cells, tumor heterogeneity
MeSH terms: Animals, Antineoplastic Agents, Collagen, Cyclophosphamide, Fibrosarcoma, Melanoma, Experimental, Mice, Inbred C57BL, Neoplasm Recurrence, Local, Neoplasm Transplantation, Neoplasms, Experimental, Neovascularization, Pathologic, Peptide Fragments, Carcinoma, Lewis Lung, Drug Resistance, Neoplasm, Endostatins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks